Skip to content
Menu

Needham Maintains Buy on Evommune, Lowers Price Target to $25

Benzinga Newsdesk 6 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Needham analyst Serge Belanger maintains Evommune (NYSE:EVMN) with a Buy and lowers the price target from $28 to $25.

Needham analyst Serge Belanger maintains Evommune (NYSE:EVMN) with a Buy and lowers the price target from $28 to $25.

Read at benzinga.com